mHSPC – Medxy AI

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.

news Oncology Urology

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY 10/30/2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.

news Oncology Radiology Urology

Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A novel PSMA PET/CT-based tumor-burden classification effectively stratifies metastatic hormone-sensitive prostate cancer patients, predicting response and prognosis with androgen receptor signaling inhibitors, especially second-generation treatments.

news Oncology Urology

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens

By MedXY 10/30/2025

This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balance efficacy and toxicity.